Search 

Celumigen Pharmaceuticals is a California- headquartered seed stage specialty pharmaceutical company in dermatology focused on developing the first FDA-approved topical prescription immunotherapeutic drug for Cutaneous viral warts; a widespread global disease affecting greater than 500MM people in China, and 78% of the world's population. The global markets have seen no approved prescription therapies for HPV, Common warts and no therapies that eradicate this disease on the market or in the pipeline-- we plan to capture and grow this lucrative market. Our therapeutic is a likely 505 (b) 2 FDA designated drug. Our leadership, development and clinical team is a group of world class leaders with deep industry knowledge and unparalleled domain expertise. We have raised a seed round led by industry- leading investors which funded a Proof of Concept study with very positive confirmatory results and data to support our Phases I and Phase II. We are now seeking strategic partnership with a company seeking to support drug development to enhance existing dermatology drug asset portfolios or fund our program through venture capital / partnership.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies.

We seek to transform the lives of people suffering from neuroscience diseases, including Parkinson’s disease, epilepsy and schizophrenia, through the development of novel therapies. We have built a highly experienced team of senior leaders and neuroscience drug developers who combine a nimble, results-driven biotech mindset with the proven expertise of pharmaceutical company drug discovery and development.

Brilliant was founded in Chengdu city in 2007, specializes in the manufacturing and sale of generic medicines, innovative biologicals, small molecules and inhaled preparations. The sales revenue in 2019 was nearly US $550 million. We have 5 R&D centers and 5 GMP factories.

中英生命科学医疗项目合作

China Meheco Group Co., Ltd. (China Meheco), established in 1984, head office in Beijing. State-owned company listed at Shanghai Stock Exchange (No 600056).
The whole industry chain includes R&D, cultivation & processing, manufacturing, distribution, logistics, international trading, academic promotion, technical service etc.
The company has established a comprehensive business framework supported by pharmaceutical manufacture. The 12 drug plants of the Group system China Meheco are located in different regions in China. All production lines are proved by GMP, Good Manufacturing Practice, etc.

A listed and famous Chinese pharmaceutical company and also the main profit center of CR pharmaceutical Group which is the 2nd largest pharmaceutical group in China. The company has rich experiences in collaboration with multinational companies such as Sanofi, Takeda, Roche, Bailey and Novo Nordisk and so on. We are looking forward to cooperating with partners whose assets could meet the unmet medical needs and whom desire to explore China market.

Connexin Therapeutics Ltd. is a UK-based biopharmaceutical company specializing in the discovery and development of drugs targeting connexins, initially for the prevention of vision loss and blindness associated with the eye disease known as glaucoma. While there are a variety of glaucoma subtypes, a common hallmark is the progressive loss of vision due to the gradual cell death in the retina and optic nerve triggered by elevated intraocular pressure. Many drugs are available to reduce intraocular pressure, yet none have been shown to directly protect cells in the retina or optic nerve, and hence prevent them from dying. Thus, vision loss inevitably occurs, even in well-treated patients, and severe vision impairment remains common in these patients.
For 20+ years, our scientific co-founder, Dr. Stewart Bloomfield, has researched and published extensively on the connexin-mediated mechanisms by which elevated intraocular pressure causes cell death in the retina and optic nerve, resulting in vision loss. His research has demonstrated three key points:

1. Retinal and optic nerve cell death is mediated by the bystander effect, which, in turn, mediated by a protein called connexin 36; and

2. Inhibition of connexin 36 prevents further loss of vision in glaucoma; and

3. This inhibition can be achieved using a small molecule drug.

Thus, our goal at Connexin Therapeutics is to develop and partner novel compounds which block connexin 36, thereby preserving vision and potentially preventing blindness in patients with glaucoma. Importantly, glaucoma patients with either elevated or normal intraocular pressure will benefit from retinal neuro-protectants, even in the presence of aggressive attempts to reduce intraocular pressure via drugs or surgery. Other ophthalmic diseases which may benefit from connexin inhibition include subtypes of glaucoma (i.e., normotensive glaucoma), retinitis pigmentosa, and the prevention of corneal scarring secondary to eye surgery. These are indications which may be pursued as the company grows.
In addition to our work with connexin 36 in glaucoma, we may have an opportunity to discover and develop a novel connexin 45 inhibitor. Preliminary work from our laboratory suggests that inhibiting connexin 45 has protective benefits in a range of ischemic ophthalmic conditions, such as diabetic retinopathy. Thus, we have the opportunity to advance two programs from the current round of financing into full development or even licensing.
Interest from multinational pharmaceutical companies in novel compounds to treat ophthalmic conditions is extraordinarily high, as these companies recognize that the rapidly aging population, coupled with significant unmet needs and favorable reimbursement policies, all make for attractive licensing opportunities for companies like Connexin Therapeutics. Thus, we anticipate initiating licensing discussions with pharmaceutical companies as novel connexin inhibitors emerge from our efforts.
Connexin Therapeutics raised ~£150,000 in Seed financing in early 2019. These funds are being used to synthesize and test novel small molecules in animal models of glaucoma. These compounds are based on a molecule which has already demonstrated efficacy in mouse models of glaucoma. Thus, these data supplement and extend the work already published.
We are currently raising ~£2,000,000 to optimize our lead compounds. After ~8-10 quarters of work we anticipate having a library of patentable compounds which are highly selective for connexin 36, backed by primate data. We will have a second compound which inhibits connexin 45 for diabetic retinopathy. Future financing rounds will take one or both leads into clinical trials, while also fueling our expansion into other indications with this same mechanism of action.

For more than 120 years, the Trade Commissioner Service (TCS) has been helping Canadian companies navigate international markets. Our trade commissioners in more than 160 cities worldwide can provide you with key business insights and access to an unbeatable network of international contacts. The TCS provides Canadian businesses and organizations with tailored advice to help them enter new markets outside of Canada.

Credevo is a global clinical research and development company that acts as an extended arm of Biopharma companies to facilitate clinical development and product registrations worldwide.

Crossject, publicly traded on the Paris exchange, has developed a proprietary, needle free auto-injector (ZENEO®) which enables the intuitive intramuscular or subcutaneous administration of pre-filled injectable drugs in less than 1/10th of a second, in only two steps (open, push on the injection site).
Crossject will commercialize, its proprietary, clinically proven needle free auto-injector through partners, a portfolio of rescue drug-device combinations, for example Epinephrine in anaphylactic shock, Midazolam in epileptic seizure, Terbutaline in severe asthma exacerbation, or Hydrocortisone in adrenal crisis.
Our innovative needle-free drug delivery based portfolio could be a great fit with your emergency care positioning. I would like to introduce you to the ZENEO® key benefits and learn more about your in-licensing strategy and how we might work together.